CG Oncology (CGON) Capital Expenditures (2024 - 2026)
CG Oncology (CGON) reported Capital Expenditures of $304000.0 for Q1 2026, up 1800.0% on a YoY basis from $16000.0 in Q1 2025, and up 4242.86% quarter-over-quarter from $7000.0 in Q4 2025.
CG Oncology (CGON) Capital Expenditures (2024 - 2026) Analysis & Trends
CG Oncology has reported Capital Expenditures for 3 years, with the latest figure at $304000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 1800.0% year-over-year to $304000.0; the trailing twelve-month figure through Mar 2026 stood at $422000.0 (up 77.31% YoY), and the FY2025 full-year result was $134000.0, down 42.74% from the prior year.
- Capital Expenditures for Q1 2026 stood at $304000.0, up from $7000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $304000.0 in Q1 2026, with the low at -$1000.0 in Q3 2024.
- Historically, Capital Expenditures has averaged $74666.7 across 3 years, with a median of $14000.0 in 2024.
- The largest YoY upside for Capital Expenditures was 9800.0% in 2025 against a maximum downside of 96.65% in 2025.
- CG Oncology's Capital Expenditures stood at $209000.0 in 2024, then tumbled by 96.65% to $7000.0 in 2025, then jumped by 4242.86% to $304000.0 in 2026.
- The last three Capital Expenditures figures came in at $304000.0 (Q1 2026), $7000.0 (Q4 2025), and $97000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | 304,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 304,000.00 |
| Mar 31, 2026 | 304,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 209,000.00 |
| Dec 31, 2024 | 209,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Mar 31, 2024 | 12,000.00 |